Table 2 Vaccines based on six Leishmania pathoantigens (H2A, H2B, H3, H4, A2 and HSP70)
Antigen | Targeted disease | Animal model | Delivery system | Result | Reference |
|---|---|---|---|---|---|
H2A/H2B/H3/H4 | CL | BALB/c | DNA vaccine | Protection | [34] |
N-terminal part-H2B | CL | BALB/c | Protein + CpG | Protection | [52] |
H2A/H2B/H3/H4 | CL | BALB/c | Ag-loaded DCs | Long-lasting protection | [53] |
H2A/H3, H2A/H4, H2B/H3, H2B/H4 | CL | BALB/c | DNA vaccine | Partial protection | [40] |
H2A/H2B, H3/H4 | CL | BALB/c | DNA vaccine | Partial protection | [54] |
H1/H2A/H2B/H3/H4 + 5 more Ags | VL | Dog | DNA vaccine | Partial protection (DLN) | [55] |
H2A/H2B/H3/H4 | VL | BALB/c | DNA vaccine | No protection | [56] |
H2A/H2B/H3/H4 | VL | BALB/c | Ag-loaded DCs | Partial protection | [56] |
A2 | CL | BALB/c | Protein + IL-12 | Partial protection | [57] |
A2 | CL/VL | BALB/c | DNA vaccine | Partial protection | [58] |
A2 | VL | BALB/c | DNA vaccine | Partial protection (liver) | [59] |
A2 | VL | BALB/c | Protein + P. acnes | Protection (liver) | [60] |
A2 | VL | Dog | Protein + saponine | Partial protection | [61] |
A2 | VL | BALB/c | A2-Adenovirus | Protection | [62] |
A2 | VL | BALB/c | L. tarentolae | Protection | [63] |
A2 | VL | BALB/c | Live bacteria | Partial protection | [64] |
HSP70 | CL | BALB/c | Primeboost | No protection | [65] |
HSP70 + HSP83 | VL | BALB/c | Protein ± ALD/MPLA | Protection (liver) | [66] |
GP63 + HSP70 | VL | BALB/c | DNA vaccine | Protection | [67] |
GP63 + HSP70 | VL | BALB/c | Protein | Protection | [68] |